Cargando…
Cyclosporine A and COVID19 – The COQUIMA cohort
Autor principal: | Sánchez-Pernaute, Olga |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772535/ https://www.ncbi.nlm.nih.gov/pubmed/33385128 http://dx.doi.org/10.1016/j.eclinm.2020.100679 |
Ejemplares similares
-
Cyclosporine A and COVID-19 – The COQUIMA cohort
por: Schuurmans, Macé M., et al.
Publicado: (2020) -
Cyclosporine A and COVID19 – The COQUIMA cohort – Author's reply
por: Guisado-Vasco, Pablo, et al.
Publicado: (2020) -
Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia()
por: Sanchez-Pernaute, Olga, et al.
Publicado: (2021) -
Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia()
por: Sanchez-Pernaute, Olga, et al.
Publicado: (2021) -
Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)
por: Guisado-Vasco, Pablo, et al.
Publicado: (2020)